All In Biotech

Drug Trial Radar · NCT01803451

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 2005

Primary completion

Aug 2026

Study completion Aug 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Mar 4, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Factorial
Masking
Single (participant)
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.

Conditions

  • Post-bariatric Surgery

Interventions

  • exendin-(9-39)Drug

    hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion

  • exendin -(9-39)Drug

    2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculatedTime frame: up to 1 year (10 sessions)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Texas Diabetes Institute - University Health System

    San Antonio, Texas · Recruiting

  • South Texas Veterans Health Care System

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.